1 |
Ali Nahit Sendur M, Aksoy S, Ozdemir NY, Zengin N, Altundag K (2012 ).What is the mechanism of progression with Trastuzumab treatment - escape or resistance? Asian Pac J Cancer Prev, 13, 5915-6.
과학기술학회마을
DOI
ScienceOn
|
2 |
Baek KH, Hong ME, Jung YY, et al (2012). Correlation of AR, EGFR, and HER-2 expression levels in prostate cancer: Immunohistochemical analysis and chromogenic in situ hybridization. Cancer Res Treat, 44, 50-6.
DOI
ScienceOn
|
3 |
Bai Q , Chen F, Qi J, et al (2007). Relationship between HER-2/neu over-expression and androgen independent prostate cancer. Zhonghua Nan Ke Xue, 13,414-6.
|
4 |
Begnami MD, Fukuda E, Fregnani JH, et al (2011). Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome . J Clin Oncol, 1, 3030-6.
|
5 |
Calvo BF, Levine AM, Marcos M, et al (2003). Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res, 9, 1087-92.
|
6 |
Carrion-Salip D, Panosa C, Menendez JA (2012). Androgenindependent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol, 41, 1128-38.
|
7 |
Di Lorenzo G, Autorino R, De Laurentiis M, et al (2004). HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori, 90, 163-70.
|
8 |
Gates JD, Carmichael MG, Benavides LC, et al (2009). Long term follow up assessment of a HER-2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Coll Surg, 208, 193-201.
DOI
ScienceOn
|
9 |
Hsing AW, Tsao L, Devesa SS (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer, 85, 60-67.
DOI
|
10 |
Lara PN, Meyers FJ, Gray CR, et al (2002). HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer, 94, 2584-9.
DOI
ScienceOn
|
11 |
Liu AN, Sun P, Liu JN, et al (2012). Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer. Asian Pac J Cancer Prev, 13, 1197-201.
과학기술학회마을
DOI
ScienceOn
|
12 |
Loeb S, Kettermann A, Ferrucci L, et al (2008). PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the baltimore longitudinal study of aging. Eur Urol, 54, 1073-80.
DOI
ScienceOn
|
13 |
Montironi R, Mazzucchelli R, Barbisan F, et al (2006). HER-2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cyst prostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol, 37, 1137-44.
DOI
ScienceOn
|
14 |
Neto AS, Tobias-Machado M, Wroclawski ML, et al (2010). Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol, 184, 842-50.
DOI
ScienceOn
|
15 |
Muhammadnejad S, Muhammadnejad A, Haddadi M (2013). Correlation of micro vessel density with nuclear pleomorphism, mitotic count and vascular invasion in breast and prostate cancers at preclinical and clinical levels. Asian Pac J Cancer Prev, 14, 63-68.
DOI
ScienceOn
|
16 |
Nath A, Singh JK, Vendan SE, Priyanka, Sinha S (2012). Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic Zone of Bihar, India. Asian Pac J Cancer Prev, 14, 63-8.
|
17 |
Neto AS, Tobias-Machado M, Wroclawski ML (2010). Molecular oncogenesis of prostate adenocarcinoma: role of the human epidermal growth factor receptor 2 (HER-2/neu). Tumori, 96, 645-9.
|
18 |
Shariat SF, Bensalah K, Karam JA, et al (2007). Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res, 13, 5377-84.
DOI
ScienceOn
|
19 |
Siampanopoulou M, Galaktidou G, Dimasis N, Gotzamani-Psarrakou A (2013). Profiling serum HER-2/NEU in prostate cancer. Hippokratia, 17, 108-112.
|
20 |
Siegel R, Naishadham D, Jemal A (2012). Cancer Statistics, 2012. CA Cancer J Clinicians, 62, 10-29.
DOI
ScienceOn
|
21 |
Tambo M, Higashihara E, Terado Y, Nutahara K, Okegawa T (2009). Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int J Urol, 16, 369-74.
DOI
ScienceOn
|
22 |
Vickers AJ, Brewster SF (2012). PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br J Med Surg Urol, 5, 162-8.
DOI
ScienceOn
|